Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2022 results: net income $6.6 million, EPS $0.29 per share.
- Period
- third quarter ended September 30, 2022
- Net income
- $6.6 million
- EPS
- $0.29 per share
- Result
- reported results
Exact text from the filing
Net loss attributable to common stockholders for the third quarter ended September 30, 2022, was $6.6 million or $0.29 per share.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at 5,000,000 shares of common stock at $1.20 per share (effective 2022-11-10).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- 5,000,000 shares of common stock at $1.20 per share
- Effective
- 2022-11-10
Exact text from the filing
On November 10, 2022, Cognition Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the public offering (the “Offering”) of 5,000,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), at a price to the public of $1.20 per share (the “Offering Price”), less underwriting discounts and commissions.
View on SEC.gov